Condition
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Withdrawn1
Active Not Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04467021Not ApplicableActive Not Recruiting
Cancer and Blood Pressure Management, CARISMA Study
NCT04216732Recruiting
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
NCT04106843Phase 2Withdrawn
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Showing all 3 trials